Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
November 23, 2015 at 08:01 AM EST
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA ...
